logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure INF-6. Estimated HCV antibody prevalence among injecting drug users – studies with national and subnational coverage [see all figures in this series...]

Part (i) All injecting drug users, 2004 - 2005


Black square = samples with national coverage; blue triangle = samples with subnational (including local or regional) coverage

Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary.

Data for Portugal, Slovenia and Slovakia are limited to prevalence among IDUs in treatment and may not be representative of prevalence among IDUs who are not in treatment.

Data for Spain and Portugal and part of the data for Czech Republic include non-IDUs and therefore may underestimate prevalence among IDUs (proportion of non-IDUs in the samples not known).

Countries are presented by order of increasing prevalence, based on the average of national data or, if not available, of subnational data.

* Czech Republic: data is from 2002-03;

Estonia: data is from 2002;

Spain: data is from 2003;

Ireland: data is from 2003;

Latvia: data is from 2001;

Sweden: data is from 2006.


SB2006: Figure INF-6 part (i)

For primary sources, study details and data before 2004, see Table INF-11 and Table INF-0.

See also 'General notes for interpreting data' on the Explanatory notes and help page.


Reitox national focal points

(see the help page for information on formats etc.)

Page last updated: Thursday, 22 November 2007